BACKGROUND: Genetic aberrations are well characterized in lung adenocarcinomas (LACs) and clinical outcomes have been influenced by targeted therapies in the advanced setting. Stereotactic body radiotherapy (SBRT) is the standard-of-care therapy for patients with nonoperable, early-stage LAC, but to the authors' knowledge, no information is available regarding the impact of genomic changes in these patients. The current study sought to determine the frequency and clinical impact of genetic aberrations in this population. METHODS: Under an Institutional Review Board-approved protocol, the records of 242 consecutive patients with early-stage lung cancers were reviewed; inclusion criteria included LAC histology with an adequate tumor sample for the successful use of next-generation sequencing and fluorescence in situ hybridization testing. Univariate analysis was performed to identify factors associated with clinical outcomes. RESULTS: LAC samples from 98 of the 242 patients were reviewed (40.5%), of whom 45 patients (46.0%) had genetic testing. The following mutations were noted: KRAS in 20.0% of samples, BRAF in 2.2% of samples, SMAD family member 4 (SMAD4) in 4.4% of samples, epidermal growth factor receptor (EGFR) in 15.6% of samples, STK1 in 2.2% of samples, tumor protein 53 (TP53) in 15.6% of samples, and phosphatase and tensin homolog (PTEN) in 2.2% of samples. The following gene rearrangements were observed: anaplastic lymphoma kinase (ALK) in 8.9% of samples, RET in 2.2% of samples, and MET amplification in 17.8% of samples. The median total delivered SBRT dose was 50 grays (range, 48-60 grays) over a median of 5 fractions (range, 3-8 fractions). The KRAS mutation was associated with worse local control (odds ratio [OR], 3.64; P<.05). MET amplification was associated with worse regional (OR, 4.64; P<.05) and distant (OR, 3.73; P<.05) disease control. CONCLUSIONS: To the authors' knowledge, the current series is the first to quantify genetic mutations and their association with clinical outcomes in patients with early-stage LAC treated with SBRT. KRAS mutations were associated with worse local control and MET amplification was associated with worse regional and distant disease control, findings that need to be validated in a prospective setting. Cancer 2017;123:3681-3690.
BACKGROUND: Genetic aberrations are well characterized in lung adenocarcinomas (LACs) and clinical outcomes have been influenced by targeted therapies in the advanced setting. Stereotactic body radiotherapy (SBRT) is the standard-of-care therapy for patients with nonoperable, early-stage LAC, but to the authors' knowledge, no information is available regarding the impact of genomic changes in these patients. The current study sought to determine the frequency and clinical impact of genetic aberrations in this population. METHODS: Under an Institutional Review Board-approved protocol, the records of 242 consecutive patients with early-stage lung cancers were reviewed; inclusion criteria included LAC histology with an adequate tumor sample for the successful use of next-generation sequencing and fluorescence in situ hybridization testing. Univariate analysis was performed to identify factors associated with clinical outcomes. RESULTS: LAC samples from 98 of the 242 patients were reviewed (40.5%), of whom 45 patients (46.0%) had genetic testing. The following mutations were noted: KRAS in 20.0% of samples, BRAF in 2.2% of samples, SMAD family member 4 (SMAD4) in 4.4% of samples, epidermal growth factor receptor (EGFR) in 15.6% of samples, STK1 in 2.2% of samples, tumor protein 53 (TP53) in 15.6% of samples, and phosphatase and tensin homolog (PTEN) in 2.2% of samples. The following gene rearrangements were observed: anaplastic lymphoma kinase (ALK) in 8.9% of samples, RET in 2.2% of samples, and MET amplification in 17.8% of samples. The median total delivered SBRT dose was 50 grays (range, 48-60 grays) over a median of 5 fractions (range, 3-8 fractions). The KRAS mutation was associated with worse local control (odds ratio [OR], 3.64; P<.05). MET amplification was associated with worse regional (OR, 4.64; P<.05) and distant (OR, 3.73; P<.05) disease control. CONCLUSIONS: To the authors' knowledge, the current series is the first to quantify genetic mutations and their association with clinical outcomes in patients with early-stage LAC treated with SBRT. KRAS mutations were associated with worse local control and MET amplification was associated with worse regional and distant disease control, findings that need to be validated in a prospective setting. Cancer 2017;123:3681-3690.
Authors: Richard J Cassidy; Xinyan Zhang; Jeffrey M Switchenko; Pretesh R Patel; Joseph W Shelton; Sibo Tian; Ronica H Nanda; Conor E Steuer; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Theresa W Gillespie; Walter J Curran; Kristin A Higgins Journal: Cancer Date: 2018-01-08 Impact factor: 6.860
Authors: Christina Wu; Terence M Williams; Evan Wuthrick; Ryan Robb; Amy Webb; Lai Wei; Wei Chen; Sameh Mikhail; Kristen K Ciombor; Dana B Cardin; Cynthia Timmers; Somashekar G Krishna; Mark Arnold; Alan Harzman; Sherif Abdel-Misih; Sameek Roychowdhury; Tanios Bekaii-Saab Journal: Clin Cancer Res Date: 2020-04-06 Impact factor: 12.531
Authors: Mathewos Tessema; Michael R Rossi; Maria A Picchi; Christin M Yingling; Yong Lin; Suresh S Ramalingam; Steven A Belinsky Journal: Lung Cancer Date: 2018-07-11 Impact factor: 5.705
Authors: Piyada Sitthideatphaiboon; Ana Galan-Cobo; Marcelo V Negrao; Xiao Qu; Alissa Poteete; Fahao Zhang; Diane D Liu; Whitney E Lewis; Haley N Kemp; Jeff Lewis; Waree Rinsurongkawong; Uma Giri; J Jack Lee; Jianjun Zhang; Jack A Roth; Stephen Swisher; John V Heymach Journal: Clin Cancer Res Date: 2020-12-15 Impact factor: 12.531
Authors: Michael S Binkley; Young-Jun Jeon; Monica Nesselbush; Everett J Moding; Barzin Y Nabet; Diego Almanza; Christian Kunder; Henning Stehr; Christopher H Yoo; Siyeon Rhee; Michael Xiang; Jacob J Chabon; Emily Hamilton; David M Kurtz; Linda Gojenola; Susie Grant Owen; Ryan B Ko; June Ho Shin; Peter G Maxim; Natalie S Lui; Leah M Backhus; Mark F Berry; Joseph B Shrager; Kavitha J Ramchandran; Sukhmani K Padda; Millie Das; Joel W Neal; Heather A Wakelee; Ash A Alizadeh; Billy W Loo; Maximilian Diehn Journal: Cancer Discov Date: 2020-10-18 Impact factor: 38.272
Authors: May Elbanna; Kevin Shiue; Donna Edwards; Alberto Cerra-Franco; Namita Agrawal; Jason Hinton; Todd Mereniuk; Christina Huang; Joshua L Ryan; Jessica Smith; Vasantha D Aaron; Heather Burney; Yong Zang; Jordan Holmes; Mark Langer; Richard Zellars; Tim Lautenschlaeger Journal: Clin Lung Cancer Date: 2020-06-02 Impact factor: 4.785